The Cameroonian government announced a decision to reduce the cost of treatment for viral hepatitis C by 50%. The measure specifically concerns the Sofosbuvir/Ledispavir 400/90 g treatment, the cost of which has been reduced from CFA50 000 to CFA25 000.
Through this decision, the government seeks to make the treatment more accessible to all. Medical staff are called to comply with it. As a reminder, the cost for the treatment based on Sofosbuvir+Velpasir 400/100 g was reduced by 75%, from CFA100,000 to CFA25,000 in November 2020.
However, according to L'Urgentiste, a website specializing in medical information in Cameroon, this new government decision hides a need to dispose of a stock of expiring drugs. "Since we do not have new stocks of drugs at the Cename (National Central Procurement Agency for essential drugs and medical consumables), we have decided to reduce the costs of the ones we have in stock by 75%. However, we have also already initiated procedures to acquire new stocks. Those willing to wait for the new stocks will wait,” a source cited by the media reported.